[Purpose] This study evaluated sexual function and risk factors in male patients on hemodialysis and also studied the efficacy of sildenafil citrate (VIAGRA®).
[Patients and Methods] A questionnaire survey was conducted among 46 male hemodialysis patients aged under 65 years (HD group) and 45 normal males (control group) for comparison. Correlations between age, history of hemodialysis, weight gain rate, DM, testosterone, BUN, prolactin, Hb, T-chol., TG, intact-PTH and β
2-MG and other factors were examined, and possible risk factors were studied. For 5 patients wishing to take VIAGRA®, it was prescribed after performing Rigiscan.
[Results] The scores for all issues in the questionnaire were significantly lower in the HD group than in the control group. However, when the ages of subjects was younger, the difference became smaller and a significant difference was no longer found for any issues when a comparison was made in patients of younger below 40. Regarding the correlation between the factors and questionnaire items, age was correlated significantry with 6 items, testosterone, and TG with 4 items, and intact-PTH with 3 items. VIAGRA® was markedly effective in 2 cases with normal Rigiscan patterns, in 1 case showing shortened episode, effective in 1 of 2 cases showing a flat trace, and ineffective in 1 case. The efficacy rate was 80%. There were no serious adverse-effect of VIAGRA®.
[Conclusion] In our study, it was confirmed that male patients on hemodialysis developed sexual dysfunction concurrently. However, it was shown that sexual function was maintained in younger patients. Age was shown to be the strongest risk factor, and the increased risk of sexual function in male HD patients became marked with aging.
View full abstract